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Abstract
DE NOVO DESIGN AND ENGINEERING OF FUNCTIONAL METAL AND PORPHYRINBINDING PROTEIN DOMAINS
by
Bernard H. Everson

Advisor: Professor Ronald L. Koder

In this work, I describe an approach to the rational, iterative design and characterization
of two functional cofactor-binding protein domains. First, a hybrid computational/experimental
method was developed with the aim of algorithmically generating a suite of porphyrin-binding
protein sequences with minimal mutual sequence information. This method was explored by
generating libraries of sequences, which were then expressed and evaluated for function. One
successful sequence is shown to bind a variety of porphyrin-like cofactors, and exhibits lightactivated electron transfer in mixed hemin:chlorin e6 and hemin:Zn(II)-protoporphyrin IX
complexes. These results imply that many sophisticated functions such as cofactor binding and
electron transfer require only a very small number of residue positions in a protein sequence to
be fixed.
Net charge and hydrophobic content are important in determining protein solubility and
stability.1,2 Accordingly, rational modifications were made to the aforementioned design
procedure in order to improve its overall success rate. The effects of these modifications are
explored using two ‘next-generation’ sequence libraries, which were separately expressed and
evaluated. Particular modifications to these design parameters are demonstrated to effectively
double the purification success rate of the procedure.
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Finally, I describe the redesign of the artificial di-iron protein DF2 into CDM13, a single
chain di-Manganese four-helix bundle. CDM13 acts as a functional model of natural manganese
catalase, exhibiting a kcat of 0.08s-1 under steady-state conditions. The bound manganese
cofactors have a reduction potential of +805 mV vs NHE, which is too high for efficient
dismutation of hydrogen peroxide. These results indicate that as a high-potential manganese
complex, CDM13 may represent a promising first step toward a polypeptide model of the
Oxygen Evolving Complex of the photosynthetic enzyme Photosystem II.
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Chapter 1: Introduction

The development of renewable, environmentally friendly energy sources is one of the
primary scientific challenges of the 21st century. Sunlight is the most abundant form of energy
available to the planet, and the rate at which the earth receives solar energy is more than
sufficient to satisfy worldwide energy consumption for the foreseeable future.3 The utility and
sustainability of solar energy over traditional fossil fuels is evident, and yet due to the inherent
limitations on any single solution it is generally accepted that a mix of solar energy technologies
will be necessary for the efficient capture and storage of this resource in the future.4
Natural photosynthesis supports all life on earth by converting solar energy to chemical
energy using a robust and self-assembling molecular mechanism. In this way, photosynthetic
organisms represent a highly sophisticated and self-replicating approach to the challange of
extracting useable energy from the sun. Nevertheless, the natural photosynthetic apparatus
suffers from at least two distinct disadvantages compared to artificial photovoltaic devices: First,
it is hampered by the need to function inside a living organism.4 And second, it is the result of
the evolutionary process, which selects for reproductive success over solar energy conversion
efficiency.5
Decades of research have led to a molecule-level understanding of the mechanisms of
natural photosynthesis.6 In essence, all photosynthetic systems consist of three parts: 1) a lightharvesting apparatus capable of creating an electronic excitation from one or more absorbed
photons; 2) a charge separation mechanism capable of shuttling a photoexcited electron from a
donor molecule to an acceptor molecule; and 3) an active site that creates some form of useable
chemical energy from the electronic excitation. As a proof of concept, many bio-inspired
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synthetic systems have been able to recreate individual aspects of the photosynthetic
mechanism.7 Unfortunately, many of these systems have proven expensive and environmentally
unsafe to produce.8 In addition, such systems are inevitably difficult to synthesize and not
scalable for global needs.
De novo protein design techniques seek to produce protein sequences from scratch with
entirely new or radically simplified folds and functions, rather than modifications of wild-type
structures.9 As a field, de novo protein design has advanced from the creation of structured
proteins10-12 to the incorporation of small-molecule binding sites13-15 on to the design of fully
active enzymes capable of novel or radically improved function.16,17 Thus, modern synthetic
biologists now have at their disposal a toolkit resulting from decades of research into the
fundamental sequence-structure-function relation in proteins.
The goal of this dissertation is to utilize the principles of de novo protein design to
develop and iteratively refine functional artificial prototypes of two photosynthetic elements.
With a focus on the radical redesign and optimization of existing biological mechanisms,
synthetic biology has been recognized as an attractive approach to the problem of adapting the
natural photosynthetic toolkit to human needs. Accordingly, this work is grounded in the decades
of research that have been devoted to uncovering and applying the design parameters of a
functional photosynthetic system.18,19
Chapters 2 through 4 of this dissertation describe the development and evaluation of a
novel de novo design technique for reliably generating diverse libraries of stable cofactorbinding protein domains. Charge separation and electron transfer events between chromophores
are the central features of the photosynthetic mechanism, and as such these events are highly
sensitive to the arrangement and spacing of these chromophores.20-22 In this context, the protein
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backbone plays a crucial role as a scaffold for positioning photoactive cofactors, and any
polypeptide model of photosynthetic mechanisms must therefore heavily feature a variety of
such scaffolds. Fortunately, de novo protein design techniques and protein folding principles are
ideally suited to the creation of protein sequences capable of binding cofactors with nativelike
structure.
Chapter 5 of this dissertation describes the re-engineering of an existing de novo
dimetalloprotein backbone into a functional di-manganese enzyme. In oxygenic photosynthesis,
the large protein complex Photosystem II (PSII) is responsible for the first steps in the sequence
of light-driven reactions necessary for catalysis. Within PSII, the Oxygen Evolving Complex
(OEC) is a tetrameric manganese complex that provides the electrons for all subsequent
photosynthetic reactions by splitting water (Eq. 1).
(1)

2H2 O ⟶ O2 + 4H+ + 4e−

As the only known example of a water oxidation catalyst in biology, the structure and chemical
function of the OEC has been the subject of detailed study for decades. Accordingly, there have
been great advances in synthetic molecular models of this system. To date, however, a de novo
protein subunit capable of water oxidation has yet to be developed. Although the goal of a de
novo water splitting enzyme has not been achieved in this work, the di-manganese system
discussed may nevertheless serve as a future engineering platform for such a functional model of
the OEC.
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Chapter 2: Pattern-based Protein Design

2.1 Porphyrin-binding Protein Design
As early as 1987, amphipathic alpha-helical bundles have been used as a target structural
motif for de novo designed proteins.23 Part of the utility of this structure is due to its high
intrinsic ‘designability’ as measured by the number of amino acid sequences with that structure
as their lowest energy conformation.24 Importantly, the four-helix bundle also features an
extended hydrophobic core consisting of opposing helical faces. This presents a well-ordered and
controllable context for the incorporation of small molecule cofactors, and thus chemical
functionality.9
One of the primary considerations in developing a functional cofactor or metal-binding
protein is structural specificity. Since the beginning of the last decade, the technique of ‘binary
patterning’ has been used with much success to reliably generate alpha helical bundles.25 This
method involves the incorporation of a repeating seven-residue pattern of nonpolar and polar
amino acids with high helical propensities, often termed the ‘heptad repeat,’ to drive the
formation of amphipathic helices. Under appropriate conditions, these helices will tend to
associate into dimers, trimers, and higher-order structures. Thus, with only consideration for the
relative hydrophobicity of amino acid types at certain regular intervals, acceptable tertiary
structure can be achieved.
2.1.1 Ternary Patterning. Although binary patterning is a conceptually simple and
useful method, natural proteins do not exclusively exhibit this pattern to yield structure. Chothia
et al. investigated the sequence-structure relationship in the Immunoglobin Variable Domain
using a residue classification scheme based on two related properties: 1) the tendency of residues
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to be found either on the interior or exterior of a folded protein; and 2) the free energy associated
with the transfer of a particular amino acid between water and an organic solvent.26 This analysis
suggests that amino acids be divided into three, rather than two categories: hydrophilic,
hydrophobic, and neutral. Hydrophilic amino acids have a negative nonpolar to polar transfer
free energy and exhibit a high tendency to appear on the exterior of the protein. Inversely,
hydrophobic amino acids have a high transfer free energy and a tendency to be found in the
hydrophobic interior of the protein. In contrast, both the transfer free energy and interior-exterior
propensity of the neutral amino acids are close to zero, indicating that residues in this group can
be found with nearly equal likelihood on the surface or in the interior of the folded protein.
In the same way that polar or nonpolar amino acids are placed at either exterior or core
positions in a binary patterning scheme, hydrophobic (core), hydrophilic (surface) or neutral
(interfacial) amino acid types could be arranged in a pattern to yield structure. The approach
outlined in this work, which seizes upon the high ‘designability’ of four helix bundles, utilizes
bioinformatically-derived design parameters to explore the space of potentially useful amino acid
sequences without a substantial loss in structural specificity.

2.2 Optimal Heme Binding Site
Natural proteins commonly adopt chemical functionality by incorporating one or more
small molecule cofactors at well-defined active sites. Accordingly and from the beginning, the
protein design community has focused on engineering cofactor binding sites into de novo protein
sequences.27,28 In the case of the single-chain alpha helical four-helix bundle motif, an ideal
porphryn binding site involves bis-histidine ligation between a pair of parallel helices. This
binding configuration is not only common in wild-type proteins and thus well characterized, but
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the favorable iron-histidine binding interaction has been shown enforce a native-like bound state
in previous de novo designed bundles, obviating the need to engineer elaborate complimentary
hydrophobic interactions in the protein core.29 Fortunately, previous bioinformatic studies have
yielded useful design parameters for this geometry and permit a maximal likelihood approach to
the incorporation of cofactors.
Negron et al. surveyed all well-resolved, non-redundant structures of porphryn binding
proteins whose ligating histidine side chains are in alpha helices, and were able to group them
according to the side-chain angles of the ligating histidine residue.30 The most populous – and
therefore the lowest energy – of these rotamer configurations is nicknamed ‘T73’ (Figure 1); T73
is a bis-histidine configuration featuring mean χ1 and χ2 torsion angles of -175° and 73°
respectively.31
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Figure 1. Representative histidine residues for each rotamer group, as identified by Negron et al.30

Within each rotamer group, all amino acid sequences within two alpha-helical turns (8
positions) of the ligating residue were aligned to yield frequency tables. By selecting those
residues that appear at each position with a frequency of at least 25%, a consensus sequence was
derived for each group. The result of this analysis suggests that only certain fixed residue
identities and positions must be included in a protein sequence in order to permit porphyrin
binding (Table 1).
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Table 1. Rotamer-dependent consensus sequences for each rotamer group.30 Residues appearing with a frequency of
at least 25% are specified, variable positions are marked as ‘X’, and ligating histidine positions are underlined.

Name
t73
m166

Consensus Sequence
IIXXXFXXHAXXGIIIF
AXXACXACHXXLA
AHXXYXXYF

t86
m80

LKXLSXFHXX

2.3 Amino Acid Probability Distribution
The value of the analysis in Section 2.1.1 is that it indicates the appropriate residues for
each solvent exposure category (core, surface and interfacial), and when paired with
bioinformatic studies of sequence-structure relationships in wild-type proteins, discrete amino
acid probability distributions for each of these categories can be derived. This allows for the
systematic implementation of a ternary pattern based design scheme: generation of sequences by
directly sampling such probability distributions for all the amino acid positions on a given
protein backbone.
Specifically, amino acid probability distributions were assigned for core, surface and
interfacial amino acid positions using the database-derived helical residue frequencies of Engel
and Degrado32 with the following modifications: First, to ensure helicity in the resulting
sequences, all residues with Chou-Fasman helical propensities 33 of less than 0.90 were
eliminated. Next, since histidine was chosen as the ligating residue at the binding site, it too was
excluded from the pool of candidate amino acids. Finally, because the eventual design goal is to
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enable electron transfer events between bound cofactors,34 the electroactive residues tryptophan,
cysteine, and tyrosine are likewise excluded.
Sequences are further simplified by eliminating side chains within solvent exposure
categories that are found with a frequency of less than 10% in these places: The hydrophobic
residues isoleucine, leucine, methionine, and valine were eliminated as candidates for placement
on the surface. Similarly, the hydrophilic residues glutamate, glutamine, lysine, and arginine
were eliminated as candidates for placement in the core. Core and surface probabilities were then
normalized for each of the remaining candidate residues within each category so that the sum of
the probabilities is 1 (see Table 2).

(2)

é
s iB - s iE
ê
p = 100 ´ ê1- N
j
j
ëê å j=1 s B - s E
i
I

ù
ú
ú
úû

Engel and Degrado did not collect side chain probabilities for interfacial residue types.
These probabilities were instead assigned according to Eq. 2 above, where p iI is the interface
probability for residue type i, N is the total number of residues under consideration in all
categories, and s iB and s iE are the probabilities given by Engel and DeGrado 32 for residue i at
typical buried and exposed positions, respectively. In this way, residues with small differences in
probability between typical buried and solvent-exposed positions are given the greatest
probability to be assigned to interfacial positions. Those residues with large differences in
probability between exposed and buried positions (phenylalanine, methionine, arginine, and
valine) are given interface probabilities of 0 and are not included in the above calculation. The
result of this analysis is the normalized probability distribution shown in Table 2 below.
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Table 2. The normalized probability distributions for core, surface, and interface positions of alpha helices. Each
entry represents the probability (normalized to 100%) that the corresponding residue will appear in the given
position category.

Residue
A
E
F
I
K
L
M
Q
R
V

Core Probability
15.8
0.0
13.8
17.4
0.0
19.3
20.1
0.0
0.0
13.4

Surface Probability
20.6
21.3
0.0
0.0
19.5
0.0
0.0
19.7
18.7
0.0

Interface Probability
19.4
14.7
0.0
15.5
15.9
15.8
0.0
18.4
0.0
0.0

2.4 Wire Frame Backbone Design
In order to utilize the aforementioned amino acid distribution, a sequence of position
categories (core, surface, interface, fixed) must be generated from an ideal wireframe backbone.
The first step is to create a four-helix backbone containing two bound cofactors, the cofactorbinding histidine ligands and a minimal cofactor-packing interface. Starting with four idealized
3.6 residue/turn alpha helices (Fig 2A), the ProtCad software package was employed to create a
D2 symmetric 35 all-alanine model helical bundle within the geometric constraints imposed by
the cofactor binding site: optimal Nε-Nε distances of 4Å 36 between pairs of ligand histidines
each in the T73 rotamer.
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Figure 2. Minimalist pathway for protein design. (A) Four idealized, 3.6 residue/turn alpha helices are arranged into
a straight D2-symmetric bundle. (B) A superhelical twist is applied to the bundle, and inter-helix spacing is adjusted
with the ProtCad software package. (C) Generic cofactor models are added, along with ligating histidine residues in
the T73 rotamer configuration, highlighted in red. (D) Consensus residues are added to the backbone, highlighted in
purple. (E) The remaining positions on each helix are assigned as core (orange), surface (green), or interface (blue)
positions by inspection. (F) A sequence is generated according to the amino acid probability distributions of Table
XX. (G) The pattern of positions is shown as a linear sequence where Z = core, U = surface, and X = interface. All
other positions are specified explicitly.

The result of this process is a bundle model with a superhelical pitch of 175Å (Figure
2B), very close to the value of 171Å found in natural Cytochrome BC1.37 Because no helix-helix

11

side chain packing interactions between pairs of adjacent antiparallel helices were considered in
this design process, the separation between these pairs of helices was chosen to be 15Å in order
to accommodate many possible pairs of side chains at interfacial positions. In accordance with
previous studies on cofactor separation and electron transfer rates,38 pairs of adjacent helices
were offset from one another such that the smallest edge-to-edge distance between cofactors was
20Å.
Binding sites were then filled with a cofactor model consisting of a disc 1.4 Å thick with
a diameter corresponding to the largest edge-to-edge distance of the porphyrin moiety of a heme
molecule, about 9 Å. Cofactor-helix and cofactor-cofactor distances in the holoprotein complex
were then adjusted with ProtCAD to remove steric clashes. After the placement of the generic
bound cofactor perpendicular to the ligand histidine Nε-Nε axis, the four side chains on each
ligating helix which form the optimal packing interface predicted on the basis of the
bioinformatic analysis of heme-binding helices, were modeled into the binding site.
Figure 2D presents an unminimized model in which each of these side chains are placed
in the lowest energy helical rotamer as predicted by Lovell et al.39 Gratifyingly, these side chains
and rotamers create a complementary surface for porphyrin ring binding which contacts roughly
75% of the possible surface area without Van der Waals clashes. As cofactor or substrate binding
using low-energy side chain conformations has been shown to be a hallmark of tight binding, this
observation indicates that such a minimalist binding site can form the basis for high cofactor
affinity.
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Starting with the model structure shown in Figure 2D, each unassigned side chain was
assigned to one of three categories – core, surface or interface – by visual inspection of each
alanine β carbon position and the direction of the Cα-Cβ bond vector. The end result of these
assignments, with Cβ atoms shown as spheres, is shown in Fig 2E.
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Chapter 3: First Generation Sequence Libraries

3.1 HPG Library
3.1.1 Algorithmic Sequence Generation. The normalized amino acid probabilities
shown in Table XX represent a discrete probability distribution within each solvent exposure
category (core, surface, or interface). Positions of a given category are assigned by sampling the
corresponding distribution. Concretely, for the arbitrarily ordered set of residues in a category, a
k

cumulant ck = å pi is constructed where pi is probability of selecting residue i. A random
i=1

number u is generated where 0 £ u £100 and the index k is found such that ck-1 < u < ck . The
residue at index k in the category is then assigned to the position in question. This procedure is
repeated for each unassigned position of the corresponding category (Fig 2G) to yield a full
amino acid sequence for the backbone structure. Figure 2F shows the end result of this process:
an unminimized backbone structure complete with a fully assigned candidate amino acid
sequence.
In order to determine the efficacy of the aforementioned approach to de novo porphyrinbinding protein design, a representative library of ten sequences was generated and targeted for
expression. Specifically, full-length sequences were produced according to the sequence
generation protocol outlined above, and candidate sequences were then screened for net charge
using a minimum absolute value of 7 at pH 7. The ten sequences resulting from this design
process, named HPG1 – HPG10 (HPG for Heme Protein Generic) are shown in Table
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Table 3. The HPG and HPGA protein sequences, and the steps in the purification process that were possible for each sequence. Helical regions are underlined
and fixed amino acid identities are highlighted in bold for each sequence.
Name

Sequence

Purification
Step1

HPG-1

QELRRHARKAIKIQEEVIAIMWILLR GGSNSGSGG RALKAHARLAIRVLQIILAIMEEVLQ GGSSTGSGG
KKLREHAKIAIQIQAIQEELQEFQKR GGSSGGSGG AQLKVHALMAIQIQQLIQAAARMLWE

HPG-2

QILAAHAALAIALQAKFIQMFWALAQ GGSNSGSGG KKLARHAKLAIELLEQALAAIEKVQK GGSSTGSGG
RQLELHAKVAIQIRKLIAKMQELIAE GGSSGGSGG QILRAHAQFAIAIRALIAIIKRVQWI

E

HPG-3

RQLAQHAKLAIKAAEKIEWMMKEIIR GGSNSGSGG ELLQQHAAIAIALMAIMIQIIERMKR GGSSTGSGG
AILRIHAEMAILVKQLKQKMLEMEAQ GGSSGGSGG ALLRLHAQMAIKFQEFEQAMKRFLWQ

E,C,P

HPG-5

ALLEQHARKAIQIEQKLLQMVWAFIR GGSNSGSGG EELREHARAAIRMFEKVERKMEKIKK GGSSTGSGG
QQLRIHAQMAIALKALAQLLAEFAER GGSSGGSGG ALLRAHAAIAIELRAVLRKLERVAWI

E,C

HPG-6

QALQEHAKEAIEVIEAAARAIWIFEK GGSNSGSGG AKLEEHAQIAIRMMKQVIQQMEAMEQ GGSSTGSGG
RALAKHARAAIEMQKMAEEFEELQEK GGSSGGSGG EELELHALFAIIMERAQEIMKEILWL

NE

HPG-7

EALEKHAAAAIALLAIVLQAMWELKA GGSNSGSGG EELERHAEIAIQALRQLLAQFEQMAE GGSSTGSGG
RILEQHAQVAIQIQEAAELFAAFQQA GGSSGGSGG IALELHAEVAIAIKQFQQEMARMKWE

NE

HPG-8

EILQAHAQAAIEMLKQFLQMFWQLEE GGSNSGSGG EELQQHAKKAIQILELAQAIIAKMIE GGSSTGSGG
KILELHAAFAIEMERMAAQMEEILQK GGSSGGSGG LQLEMHAKLAIELEEIAKQFERAEWL

E

HPG-9

KILEKHAELAIALIAKFAEIVWEMEQ GGSNSGSGG EALAEHAQEAIAIFEAAIKEMQKAAA GGSSTGSGG
AILQEHARIAIALAQIAKELAEMKQE GGSSGGSGG ALLKVHAEFAIKAQAMQEEAQEVLWQ

E,C,P

HPG-10

EKLAQHAELAIQILEEALEMVWEIKK GGSNSGSGG QALAAHAAAAIELIQQMIRAVQEVIE GGSSTGSGG
EQLAAHAEAAIAIRRIARQIAEIEEE GGSSGGSGG LLLQMHAIVAIAIERMKAAAEEIEWE

E,C,P

HPGA-3

RQLAQHAKLAIKAAEKAEWAAKEAIR GGSNSGSGG ELLQQHAAIAIALMAIAIQIAERAKR GGSSTGSGG
AILRIHAEMAILVKQAKQKALEAEAQ GGSSGGSGG ALLRLHAQMAIKFQEAEQAAKRALWQ

E,C,P

HPGA-9

KILEKHAELAIALIAKAAEAAWEAEQ GGSNSGSGG EALAEHAQEAIAIFEAAIKEAQKAAA GGSSTGSGG
AILQEHARIAIALAQAAKEAAEAKQE GGSSGGSGG ALLKVHAEFAIKAQAAQEEAQEALWQ

E,C,P

HPGA-10

EKLAQHAELAIQILEEALEAAWEAKK GGSNSGSGG QALAAHAAAAIELIQQAIRAAQEAIE GGSSTGSGG
EQLAAHAEAAIAIRRAARQAAEAEEE GGSSGGSGG LLLQMHAIVAIAIERAKAAAEEAEWE

E,C,P

1: NE = no expression, E = expression successful, C = fusion protein successfully cleaved, P = protein fully purified and stable
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E

3.2 Materials and Methods
3.2.1 Protein Preparation. Genes encoding all sequences were purchased from
Biomatik, Inc. (Cambridge, ON) with an N-terminal TEV cut site and inserted between the
BamHI and XhoI restriction sites of pET32a (+) (Novagen), which expresses proteins as His6tagged thioredoxin fusions.29 Site-directed mutants were generated using the Quickchange XL
Site directed mutagenesis kit (Agilent Technologies, Santa Clara, CA).
Proteins were expressed in E. coli BL21 (DE3) in TPP media solution.40 Cells were
grown at 37°C to an OD600 of approximately 1.0, induced with 1mM IPTG, and shaken at 25°C
for an additional 4-5 hours. Cells were pelleted by centrifugation, lysed using a French press, and
purified on a Ni-nitrilotriacetic acid column (Qiagen, Inc.). Initial attempts to perform Ni-NTA
column purification under native conditions proved largely unsuccessful due to significant
aggregation. A more productive strategy involving the use of a denaturing wash buffer (50mM
NaH2PO4, 300mM NaCl, 20mM imidazole, 6M Urea, pH 8.0) and a denaturing elution buffer
(50mM NaH2PO4, 300mM NaCl, 250mM imidazole, 4M Urea, pH 8.0) was ultimately adopted.
The eluted fusion protein was dialyzed into 50mM Tris-HCl, 0.5mM EDTA, 0.5M Urea, 1mM
DTT, pH 8.0 and then cleaved for at least 5 hours at 25°C with His6-tagged TEV protease
(Invitrogen, Inc.). The post-cut protein mixture was then dialyzed into a low-urea wash buffer
(50mM NaH2PO4, 300mM NaCl, 20mM imidazole, 1M Urea, pH 8.0) and filtered through Ninitrilotriacetic acid resin. Purified protein was brought to a working concentration using a stirred
pressure cell (EMD Millipore, Inc.), and dialyzed into 100 mM Tris, pH 8.0 for experiments.
3.2.2 Solution Molecular Weight Determination. Oligomerization states were
determined using size exclusion chromatography on a Shimadzu HPLC pump (Shimadzu Inc.,
Kyoto, Japan) equipped with a SPD-M20A diode array detector and a TSKGel G4000SW 125–5
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300 x 7.5 mm column (Tosoh Bioscience LLC). Protein was eluted at a 0.5 ml/min flow rate and
elution was monitored at 280 nm. The column was standardized using a gel filtration standard
mix containing thyroglobulin, bovine γ-globulin, chicken ovalbumin, equine myoglobin, and
vitamin B12 (Bio-Rad Laboratories, Inc).
3.2.3 Heme Affinity Measurement and Complex Formation. Hemin stock solutions of
approximately 0.5−1.0 mg/mL were prepared in DMSO and used within 6 h. Stock solution
concentrations were determined using the pyridine hemochrome assay.41 In oxidized binding
experiments, 0.5−2 μL aliquots of a hemin solution, consisting of approximately 0.1 molar equiv,
were added via gastight syriange to a stirring 4 mL solution of 2−3 μM protein, with a 10 min
equilibration delay between additions. Heme binding was monitored by the loss of absorption at
385 nm due to free hemin, and the concomitant appearance of a sharp Soret band at 412 nm,
corresponding to heme bound to the protein via bis- histidine axial coordination. The number of
heme binding sites was quantified for each protein from plots of the Soret maximum at 412 nm
versus the number of equivalents added.
Binding affinities of ferrous hemes were determined using the method I described
previously.42 Briefly, 9.0 mL of ∼3 μM protein was made anaerobic by extended flushing with
nitrogen in a Dutton cuvette,43 and the solution potential was reduced to less than −450 mV
versus NHE by the addition of a small volume (<20 μL) of sodium dithionite dissolved in
degassed 100 mM KOH. The solution potential was monitored throughout the binding titration
and kept below −450 mV by periodic additions of microliter volumes of sodium dithionite.
Hemin was added in approximately 0.1 molar equiv aliquots, and spectra were recorded after a
>10 min equilibration period. Kd,Red values were obtained from plots of the Soret band
absorbance measured at 436 nm versus the concentration of hemin added and fit with equation 3:

17

∆𝐴 = Astart + εunb [hem] + εbnd [prot] ∙ [

(3)

Kd +[hem]+[prot]−√(𝐾𝑑 +[hem]+[prot])2 −4[hem][prot]
]
2[prot]

For mixed hemin:chlorin and hemin:Zn(II)-protoporphyrin IX complex formation, singlehistidine knock-out protein samples bound to a single equivalent of hemin were first prepared as
above. After addition of a full equivalent of heme, these samples were then passed over a PD-10
desalting column (GE Healthcare, Piscataway, NJ) to remove excess DMSO. Protein-heme
complex concentrations were calculated using the bound heme Soret peak at 412 nm.
3.2.4 Fluorescence Spectroscopy. Fluorescence spectra collected as a function of heme
oxidation state were performed on an Olis DM 45 spectrofluorimeter running Olis GlobalWorks
software. Solutions were degassed under a flow of N2, and further O2 removal was carried out
using a glucose oxidase/catalase enzymatic system44 consisting of 2% glucose with 25 units/ml
glucose oxidase, and 250 units/ml catalase45,46 in the cuvette. Proteins were reduced using 0.20
mM NADPH and 0.25 µM Ferredoxin-NADP reductase. Reduction was verified by UV-Vis
spectra. Cofactor fluorescence intensities were recorded with 0.6 mm and 1.24 mm slits width
for excitation and emission respectively. Excitation wavelengths of 550 nm, 600 nm, and 630nm
were used for Zn(II)-protoporphyrin IX, Zn(II) chlorin e6, and zinc phthalocyanine cofactors
respectively.
3.2.5 Determination of Reduction Potentials. Potentiometric titrations were performed
using the method of Dutton:43 Concentrated solutions of hemoprotein prepared in advance were
diluted to 20−30 μM into a solution containing the corresponding apoprotein (>100 μM) to
eliminate the possibility of heme dissociation upon reduction.42 Mediator concentrations were:
2,3,5,6-tetramethylphenylenediamine (25uM), 1,2-napthoquinone (25uM), phenazine
methosulfate (20uM), Duroquinone (50uM), Pyocyanine (1uM), Indigotrisulfonate (1uM),
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indigo carmine (1uM), indigotetrasulfonate (1uM), 2-hydroxy-1,4-napthoquinone (25uM),
phenazine (20uM), anthroquinone-2-sulfonate (20uM), benzyl viologen (1uM), and methyl
viologen (1uM). Reported reduction potentials are referenced to the standard hydrogen electrode.
All titrations were performed anaerobically using microliter additions of freshly prepared sodium
dithionite to adjust the solution potential to more negative values and potassium ferricyanide to
more positive values. Potentiometric titrations were analyzed by monitoring the absorbance band
at 558 as the heme protein was reduced or oxidized. The data were fit with the Nernst equation
using an n value of 1.0.
3.2.6 Circular Dichroism Spectroscopy. Circular dichroism spectra were recorded on a
JASCO J-810 sepectropolarimeter in a quartz cell of 0.1cm light-path, using a bandwidth of 1nm
and a scan speed of 50nm/min. Protein solutions were 10-20 µM. Spectra were collected
between 200nm and 350nm with background correction and observed as ellipticity (obs, mdeg).
The mean residue ellipticity ([],degcm2dmol-1) were calculated using Eq. 3 below where
MRW is the mean residue molecular weight, c is the sample concentration in mg/ml, and l is the
light-path length of the cell in cm.

(3)

[]=[]obs [MRW/(10lc)]

Protein secondary structure percentages were calculated with the program K2d 47 using data
points ranging from 200nm to 240nm.
3.2.7 Nuclear Magnetic Resonance Spectroscopy. All NMR experiments were
performed at 20oC on Varian Inova spectrometer operating at a 600MHz and equipped with a
triple resonance cryogenic probe capable of applying pulse field gradients in the z-direction.
Chemical shifts are referenced to water at 4.77 ppm for 1H. Data were processed using the
program NMRPipe 48 and analyzed using Sparky.49 Unlabelled protein samples were exchanged
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into deuterium oxide buffer containing 200 mM d9-Tris, pD 8. All samples were 300-400 µM in
four-helix bundle concentration. One-dimensional 1H spectra and two-dimensional 1H-13C
sensitivity-enhanced constant-time heteronuclear single-quantum coherence (13C-HSQC) spectra
were collected as described previously.15
For histidine side chain rotamer determination 4D 13C/13C separated HMQC-NOESYHMQC spectra 50 were collected on reduced U-13C,15N-L-histidine-labelled holoprotein samples
with sweep widths of 10,000 Hz for 1H and 2000 Hz for 13C utilizing Wurst140 decoupling of
the full 13C spectral width (140ppm) and a mixing time of 150 ms. Reduced samples were
prepared by degassing in a 9 inch NMR tube using multiple cycles of vacuum and argon,
reducing with excess dithionite and then flame sealing.

3.3. Solubility and Heme Binding in Algorithmically Generated Sequences
Of the ten sequences discussed above, three did not express even at lowered (16°C)
temperatures. Of the seven that did express, five were soluble as thioredoxin fusions after
denaturing purification. And of these five soluble fusion proteins, three were soluble after
cleavage from the thioredoxin domain: HPG-3, HPG-9, and HPG-10. CD analysis of these three
proteins confirms their helical nature (Fig 4) and size exclusion chromatography demonstrates
that they are monomeric. Attempts to refold the other proteins in the presence of hemin in order
to enhance solubility or structural stability proved unsuccessful.
Each of the three soluble proteins was assayed for ferric heme binding. No binding is
observable as detected by the appearance of a bis-histidine Soret peak at or near 412 nm after 24
hour incubations at a range of temperatures and solvent pH values. Results from my previous
work 51 and that of others 52 has demonstrated that many designed proteins feature an over-
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stabilized apo state with low solvent accessibility to the binding pocket. Thus, significant
chemical denaturation is often required to coerce the protein into an open conformation where
binding can occur.52-54 However, attempts to partially destabilize the proteins in order to increase
the stability of this open state, using urea and guanidine hydrochloride in combination with
elevated temperatures as has proven successful for other designed proteins, were likewise
unsuccessful.
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3.4 HPGA Sequences: Binding Pocket Redesign
Figure 3. Opening a cavity for porpyryn-biding in the protein core. (A) An unminimized model of HPG-9 with
fixed consensus sequence positions shown in red. Large hydrophobic residues on adjacent helices, likely to be a
steric hinderace to porpyryn binding, are highlighted with gold spheres. (B) An unminimized model of HPGA-9,
where problematic residues of part A have been mutated to alanine. (C) The pattern of residue positions used in the
HPG library, where Z = core, U = surface, and X = interface. Fixed consensus sequence positions are shown in
magenta. (D) The pattern of residue positions used for the HPGA and subsequent libraries, with an expanded set of
fixed residue identities shown in magenta.

The failure of HPG-3, HPG-9, and HPG-10 to exhibit ferric heme binding even after
treatment with denaturants suggests that while the T73 consensus sequence may be necessary, it
is not sufficient to ensure bis-histidine porphyrin binding between alpha helices. Thus, it is likely
that more sequence information must be specified. Figure 3A depicts a simple, unminimized
model of HPG-9 in which each side chain is in its lowest energy helical rotamer.39 The
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bioinformatically derived sequences that were used in this design process only fix residue
identities in the helices which contain the ligand side chains. For this reason, possible steric
clashes with nonligand helices were not considered in the original design of the binding pocket.
From Figure 3A, it is clear that three positions on each nonligand helix pose a high risk of steric
hindrance to binding.
To remedy this, each of the three soluble proteins was altered by alanine mutation at each
side chain position that was identified as a possible obstruction (see Figure 3B, sequences in
Table 3). All three of these proteins, the new versions of which are termed HPGA-3, HPGA-9,
and HPGA-10 (see Table 3), are soluble monomers when cleaved from their fusion partners and
are more alpha helical as assayed by circular dichroism (Figure 4). The latter is not surprising, as
several side chains have been replaced with the one known to have the highest helical
propensity.55
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Figure 4. Circular dichroism spectra for (A) HPG-3 (gray) and HPGA-3 (black), (B) HPG-9 (gray) and HPGA-9
(black), and (C) HPG-10 (gray) and HPGA-10 (black) apo proteins. (D) A table of alpha helical content (in percent)
for each protein, as calculated by the K2d software package. 47 In all sequences, alanine mutations result in an overall
increase in helical content.
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3.5 Heme Affinity and Binding Pocket Characterization
Figure 5. Single-site ‘knock-out’ binding sequences of HPGA-9 and HPGA-10. (A) Sequences with a deactivated
binding site between helices 1 and 3. ‘Knock-out’ phenylalanine mutations are indicated in red, and preserved
hisitdine positions are in bold. (B) Sequences featuring a deactivated binding site between helices 2 and 4. Cartoon
insets indicate the location of functional binding sites.

Of the three alanine-mutated proteins, HPGA-9 and HPGA-10 both bind heme in an
oxidized and reduced state. HPGA-9 binds two equivalents while HPGA-10 binds only one.
‘Knock-out’ mutations were made to each binding site of each sequence by replacing one or both
of the ligating histidines with phenylalanine (Figure 5). These mutations allow us to determine
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the binding constants independently for each site in HPGA-9. The fact that only one such knockout sequence in HPGA-10 can bind heme indicates that the sole functional binding site of that
protein lies between the second and fourth helices (not shown).

Figure 6. Characterization of heme binding in HPGA-10. (A) Bound heme spectra in both oxidized and reduced
states. (B) Oxidized heme binding titration of HPGA-10 (circles), fit with equation 3 (red line). (C) Determination
of bound heme reduction potential, fit with the single-electron Nernst equation (red line). (D) Reduced heme binding
titration, fit with equation 3. Inset is a cartoon diagram of HPGA-10, indicating the location of the functional
binding site.
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Figure 6 above depicts the bound heme spectra in both the ferric and ferrous states, the
determination of the ferric and ferrous heme binding constants, and the bound heme reduction
potential of the single heme that binds HPGA-10. The bound heme reduction potential, -146 mV
vs NHE (see Table 5), is more than 100mV more positive than observed in previous heme
protein designs.56-58 Gibney and coworkers have demonstrated that the bound heme reduction
potential directly determines the ratio of oxidized and reduced heme binding affinity59,60 with
higher potential heme-protein complexes having weaker ferric and stronger ferrous affinities. My
findings for HPGA-10 reflect this, with reduced heme dissociation constants within error of
those observed for my previous intentionally designed hemoproteins HP7 58 and H4,34 and
oxidized binding 5-fold to 10-fold weaker.
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Figure 7. Characterization of heme binding in HPGA-9. (A) Representative bound heme spectra in both oxidized
and reduced states. (B) Reduced heme binding titration for the binding site located between helices 1 and 3 (circles)
fit with equation XX (red line). Inset is the corresponding oxidized binding titration for this site, wherein binding is
too tight to reliably fit with equation XX. (C) Potentiometric titration of the diheme protein (both binding sites
intact), fit with a single-site, single-electron Nernst equation (red line). (D) Reduced heme binding titration for the
binding site located between helices 2 and 4 (circles) fit with equation XX (red line). Inset is the corresponding
oxidized binding titration for this site.

HPGA-9 binds two molecules of hemin. Due to the large degree of spectral overlap and
the similar binding constants at the two binding sites, the two HPGA-9 binding site knock-out
proteins were used to independently determine their ferric and ferrous heme affinities (see Figure
5). The reduction potentials at the two sites are the same, within error, of each other. Figure 7C
depicts the potentiometric titration of the diheme protein fit with a single one-electron transition.
The fit potential is the same as those independently determined for the two single heme knock-
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out proteins (not shown). This demonstrates that binding of either heme has little effect on the
global structure of the protein, a property distinct of that seen in other designed diheme four αhelix bundles.61,62

Table 4. Heme binding constants for the functional binding sites of HPGA-9 and HPGA-10.

Protein

Location

Kd Oxidized

HPGA-9
HPGA-9
HPGA-10

Helices 1-3
Helices 2-4
Helices 2-4

25.2 +/- 9 nM
77.3 +/- 16 nM
3.5 +/- 1.2 μM

Kd Reduced
(μM)
1.5 +/- 0.4
4.6 +/- 0.5
3.8 +/- 0.2

Em
(mV)
-168 +/- 3
-168 +/- 3
-146 +/- 4

As the data above shows, half of the binding sites in soluble sequences successfully
bound heme after modification of the binding pocket. An inspection of the sequence features of
the unsuccessful binding sites suggests that large or charged residues at certain nearby positions
might disrupt heme binding. In HPGA-10, binding might be disrupted between helices 1 and 3
due to GLN at position 2, approximately one helical turn ‘above’ the ligating histidine at position
6. In HPGA-3, the presence of LYS at position 2 and GLU on the adjacent helix 3 at position 71
might prevent binding in much the same way. In a similar manner, between helices 2 and 4, the
presence of LEU at positions 37 and 106 might contribute to the disruption of binding.
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3.6 Structural Characterization
3.6.1 Backbone Structural Specificity. Although backbone 15N-HSQC spectra are
commonly used to demonstrate structural specificity in proteins,12,63 neither HPGA-9 nor HPGA10 were soluble at solution pH levels low enough to prevent amide proton exchange with solvent
on the NMR time scale. Figure 8 depicts the the natural abundance 13C-HSQC spectrum of
diheme HPGA-9. The low level of chemical shift dispersion observed in Figure 8A and B
coupled with the similarity of the apo and holoprotein spectra indicate that HPGA-9 does not
undergo a large structural organization upon heme binding, and may not adopt a single nativelike
holo state.

Figure 8. Natural abundance 13C-HSQC spectra of (A) apo and (B) holo HPGA-9 samples. Similarity between the
spectra indicates that HPGA-9 does not undergo a large structural change upon binding.

3.6.2 Geometry of Porphyrin-Ligating Residues. As outlined in Section 2.2, the HPG
sequences were designed to enforce the bis-his ligation of heme with histidines in the T73
rotamer. In HPGA-10, this design feature was confirmed by directly probing its histidine
geometry via NMR spectroscopy. A ‘knock-out’ version of the HPGA-10 sequence was prepared
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where both histidines in the inactive binding site (HIS6 and HIS76) were mutated to
phenylalanine (Figure 5). This sequence, HPGA-10-H6FH76F, was then expressed to selectively
incorporate uniformly 15N, 13C-L histidine residues into the functional binding site.64 Fourdimensional 13C/13C separated HMQC-NOESY-HMQC NMR spectra were then collected on
reduced holoprotein samples.50,65

Figure 9. Structural characterization of heme-bound histidine geometry in HPGA-10H6FH76F. (A) 13C-HSQC
spectra of labeled HPGA-10H6FH76F, showing the chemical shifts of the carbon atoms of H41 and H111. (B)
13 13
C/ C HMQC-NOESY-HMQC spectra of reduced holo HPGA-10H6FH76F, showing selected crosspeaks between
nearby carbon-bound protons of H41 and H111.

In this experiment, cross-peak intensities indicate the relative distances between the 13Cbound protons within labeled residues according to equation 4, where 𝑟𝑖 is an unknown
interproton distance, 𝑟𝑟𝑒𝑓 is a known interproton distance, and 𝑆𝑟𝑒𝑓 and 𝑆𝑖 are their respective
NOE cross-peak intensities.66
(4)

𝑆𝑟𝑒𝑓 1/6

𝑟𝑖 = 𝑟𝑟𝑒𝑓 (

𝑆𝑖
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)

Figure 10 below shows the relevant carbon-bound 1H-1H distances for the T73, M166, T86 and
M80 rotamers as defined by Negron et al.30 With respect to the interproton distances of all the
rotamers in this group, T73 is distinguished primarily by a large (4.7Å) separation between its
Cβ and Cδ-bound protons (Figure 10A). Moreover, in all of these configurations, the Cε-bound
proton and the Cδ-bound protons maintain a constant distance of 4.3Å since they are both bound
to the imidazole ring. Using 1Hε-1Hδ and 1Hβ-1Hδ cross-peak intensities as 𝑆𝑟𝑒𝑓 and 𝑆𝑖
respectively, it is therefore possible to determine the characteristic 1Hβ-1Hδ interproton distance.
Using the cross-peak intensities from the spectra shown in Figure 9B above, this separation was
calculated to be 4.6Å. Thus, it is likely that the ligating histidines in HPGA-10 adopt the
extended histidine conformation of the T73 rotamer.

32

Figure 10. Important inter-proton distances for representative models of the histidine rotamers identified by Negron
et al.30 Shown are the distances between Ca, Cb, and Cd-bound protons for the (A) T73, (B) M166, (C) T86, and (D)
M80 rotamers.

3.7 Electron Transfer in Mixed-Cofactor Complexes
The HPG/HPGA proteins were designed to support electron transfer between cofactors.
As a prerequisite, they must be capable of simultaneously accommodating a heme and a separate
cofactor that can serve as a light-activated primary donor in the electron transfer reaction.
Previous work has demonstrated that zinc porphyrin cofactors can be bound at de novo designed
bis-histidine binding sites by eliminating one of the ligating histidines.34,67 Accordingly, a singlehistidine knock-out of HPGA-9 (HPGA-9-H111F in Figure 5), which features a functional bishistidine binding site and a monohistidine site, was selected for further screening. To check for
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complex formation, HPGA-9-H111F was loaded with one equivalent of heme at the bis-histidine
site and separately titrated with Zn(II)-protoporphyrin IX, Zn(II)-chlorin e6, Zn-phthalocyanine
and Zn-tetraphenylporphyrin. Figures 11A and 11B below show that Heme: Zn(II)protoporphyrin IX and Heme: Zn(II)-chlorin e6 complexes can be formed without disruption of
the heme site.
Fluorescence intensity assays were performed to determine if these complexes are
capable of electron transfer. Specifically, if the photoexcited state of the Zn(II) porphyrin
cofactor can relax via electron transfer to the heme, then reduction of the heme should block this
relaxation pathway. Therefore, an increase in flourescense intensity of the Zn(II) cofactor in the
reduced complex is evidence for electron transfer.68 Figures 11C and 11D show such an increase
in florescence intensity going from the oxidized (black) to reduced (red) states in both
complexes.
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Figure 11. (A) Absorbance spectra of the Hemin:Zn(II)-protoporphyrin IX complex of HPGA9-H111F in the
oxidized (black) and reduced (red) states. (B) Absorbance spectra of the Hemin:Zn(II)-chlorin e6 complex of
HPGA9-H111F in the oxidized (black) and reduced (red) states. (C) Oxidized (black) and reduced (red)
fluorescence emission spectra of the Hemin:Zn(II)-protoporphyrin IX complex excited at 418nm, showing an
increase in fluorescence emission intensity when heme is reduced. (D) Oxidized (black) and reduced (red)
fluorescence emission spectra of the Hemin:Zn(II)-chlorin e6 complex excited at 418nm, showing an increase in
fluorescence emission intensity when heme is reduced.

3.8 Conclusions
The above results demonstrate that sophisticated functions such as cofactor binding and
electron transfer can be engineered into a protein by specifying only a small number of fixed
amino acids in its sequence. In order to draw useful conclusions for future protein design
projects, it is instructive to look at the success rate of this approach compared to those of other
similar protein design efforts. Of all thirteen sequences generated, two were shown to bind heme
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with a satisfactory level structural specificity. Of these two successful proteins, HPGA-9 was
capable of accommodating a variety of photoactive Zn(II) porphyrin cofactors and was further
shown to exhibit light-activated electron transfer between cofactors. Therefore, this procedure
can be considered to have a 15% success rate for cofactor binding, or an 8% success rate for
electron transfer function.
A brief survey of success rates from other modern de novo design efforts shows rates
ranging from 2 - 44%, with most surveyed methods yielding fewer than 15% successful
sequences.69-73 Such a comparison of success rates is inherently complicated by small sample
sizes and the differing criteria for success across projects. Nevertheless, the above numbers
indicate that a propensity-weighted patterning approach to protein design, such as I describe,
yields successful sequences with a frequency similar to other more computationally expensive
methods.
One advantage of this method is that it generates sequences from a discrete probability
distribution of amino acids, thereby permitting a rough estimation of the possible number of
functional proteins it can produce. Assuming that 8% of sequences are capable of both heme
binding and electron transfer, and using the alanine-mutated sequence pattern shown in Figure
3D, it is estimated that 5.6 x 1045 distinct functional proteins can be generated with this
procedure.
This astronomical number represents a volume in ‘sequence space’ much too large for
evolution to have explored, and this study implies that evolution did not need to exhaustively
search this space in order to achieve functional success. With respect to de novo protein design,
this is evidence that a successful strategy need not account for the numerous unnecessary
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constraints associated with the long evolutionary history of natural proteins; functional
sequences only require the explicit identification of a few key residues.
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Chapter 4. Next Generation Sequence Libraries: Charge and Hydrophobicity

4.1 Net Charge and Hydrophobicity in Designed Protein Sequences
Given the large number of functional sequences that can be produced by the design
procedure described in Chapters 2 and 3, an 8% success rate implies that a proportionally larger
number of candidate sequences must be expressed and tested before functional proteins can be
identified. This presented a significant challenge to the experimental verification of this protein
design protocol and highlighted the need for improvements. In the library of designed sequences
shown in Table 3, only three of the ten members of the HPG library were soluble enough to be
fully purified. Thus, to a first approximation, any attempt to improve this procedure first has to
address the issue of protein solubility.
In 2007, Liu and coworkers demonstrated that placing a large number of similarly
charged amino acids at solvent-exposed positions in natural proteins was sufficient to prevent
their aggregation in the unfolded state and impart remarkable resilience in the form of refolding
after denaturation.1 This ‘supercharging’ technique resulted in net charge counts ranging from
+48 to -30, yet these highly modified proteins retained the function of their wild-type
counterparts. The dual benefits of solubility and resilience may come at the cost of overall
structural stability, however, as repulsion between residues of a similar net charge is known to
decrease stability in natural proteins74 and extreme net charge has been identified as a hallmark
of intrinsically disordered protein sequences.75
De novo designed proteins generally feature a number of energetically favorable
interactions that stabilize a native folded state and, as such, are usually more stable than
comparable natural proteins. The incorporation of high net charge into a protein design scheme
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may therefore be a promising strategy to increase solubility in designed proteins, as their
inherent stability may account for the effects of their net charge.
The folding of globular proteins is stabilized primarily through the burial of nonpolar
residues into a hydrophobic core.76 These hydrophobic interactions are nonspecific, and the
presence of many nonpolar residues might therefore lead to multiple conformations of the
polypeptide chain that are more stable than the unfolded state.77 For many sequences in the HPG
library, the observed propensity for aggregation suggests that an amyloid-like state might be the
most stable conformation of the protein chain. Therefore, a decrease in overall hydrophobicity
might destabilize such aggregates and promote a more soluble monomeric native state in
generated sequence libraries.

4.2 Modifications to the Sequence Generation Algorithm
The effects of modulating net charge and hydrophobicity in the aforementioned design
process were explored via modifications to the procedure of Chapter 2. First, the optimal heme
binding site consensus sequence (Section 2.2) was expanded to include the alanine residues on
non-ligating helices near each binding site (Section 2.4). Next, to probe the effects of net charge
on protein solubility, a library of ten sequences was generated with this consensus sequence and
with the rule that each of the four helical regions should separately have a net charge of at least
+5 or at most -5 for net positive or net negative sequences, respectively. The original amino acid
probability distribution shown in Table 2 was used. The ten sequences (HS-1 to HS-10) resulting
from this modification to the charge cutoff rule are shown in Table 6.
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Table 5. The HS protein sequences, and the steps in the purification process that were possible for each sequence. Helical regions are underlined and fixed amino
acid identities are highlighted in bold for each sequence.
Name
Sequence
Purification
Step1
HS-1

AALEEHAKLAIRIIRQALRAAKKAIK GGSNSGSGG QKLRAHARQAIKALEAAIKAALQAKQ GGSSTGSGG
AQLKAHARMAILLRKALKLAQQAAEK GGSSGGSGG LKLRAHAQVAILLRQAARLAKQALKL

E,C

HS-2

RALERHARKAIQFLRAALAAAKAAKE GGSNSGSGG QILRKHARLAIRIAAKAIKQAQRAIA GGSSTGSGG
EALKKHAKLAIIIERAERIAIRAARR GGSSGGSGG KALRMHAALAIQVQQALAKAAKAQKA

E,C

HS-3

EALREHAQKAIRMQRKAQRAAKQAAQ GGSNSGSGG RILQRHAKIAIRVIKLAAELAKKALR GGSSTGSGG
RALKLHAQMAIQVREAQKIAAAAARR GGSSGGSGG LALKMHAKAAIIFKKAQQQARAAKAE

E,C

HS-4

AKLREHAEKAIKIKRQAQEAAAKALK GGSNSGSGG RKLAQHAQQAIAIARKALRLAQQALA GGSSTGSGG
KLLKEHAQAAIKFKAAKREAAQAIRR GGSSGGSGG EILRMHAKLAIKFQAAAQAAKKAAAK

E,C

HS-5

EQLRKHAEKAIKLQAAALRAAKAAKQ GGSNSGSGG QQLREHAQKAIKLVKEAIRQAIKAIR GGSSTGSGG
QLLREHARMAIQFRAAQAIAAKAKKA GGSSGGSGG AQLQMHAAVAIILERAQKIAKRAQRK

E,C

HS-6
HS-7
HS-8
HS-9
HS-10
HS-7-W

EILQQHAQLAIQAEAQAQEAAQEAAE GGSNSGSGG ALLEQHAQIAIKIVEAAEEIAQEAAE GGSSTGSGG
AELQEHAEIAILIKQAQEEAQAAIQE GGSSGGSGG IQLEFHAEIAIEFERAEEEAAQAKAA
EALEEHAELAIEALEIAQEAAKQAKA GGSNSGSGG AILAEHAKAAIQIVEEALQEAQEALE GGSSTGSGG
QELEIHARFAIALAEAAEAAQQAEAE GGSSGGSGG EELEMHAAIAIQLEQALEEARRAEEQ
QELERHAAQAIAMEQKALQAAEEAEE GGSNSGSGG EALERHAEIAIEIMEEAEELALKAQK GGSSTGSGG
RILEIHAEIAIAIEEAEKAAEAAAAE GGSSGGSGG IALEIHAAIAIAVQEAEEIAEKAEQE
EILQAHAEIAIALEALAIAAAALAEE GGSNSGSGG EELEAHAEAAIRFAALAEEQAAQALQ GGSSTGSGG
EELQEHARLAIEAREALEQALEAIER GGSSGGSGG QLLAVHAQFAIAMEEALEQAAEAAQE
EELEEHAQAAIALLELAQAAAAIAQA GGSNSGSGG QELKEHAAEAIAIAEAAEELAQEALK GGSSTGSGG
EQLEIHAEFAIQAEEAAEAAEEAQKK GGSSGGSGG EQLQLHALMAIKFKQAEEEAEEAQEL
EALEEHAELAIEALEIAQEAAWQAKA GGSNSGSGG AILAEHAKAAIQIVEEALQEAQEALE GGSSTGSGG
QELEIHARFAIALAEAAEAAQQAEAE GGSSGGSGG EELEMHAAIAIQLEQALEEARRAEEQ

EILQAHAEIAIALEALAIAAAWLAEE GGSNSGSGG EELEAHAEAAIRFAALAEEQAAQALQ GGSSTGSGG
EELQEHARLAIEAREALEQALEAIER GGSSGGSGG QLLAVHAQFAIAMEEALEQAAEAAQE
EELEEHAQAAIALLELAQAAAWIAQA GGSNSGSGG QELKEHAAEAIAIAEAAEELAQEALK GGSSTGSGG
HS-10-W
EQLEIHAEFAIQAEEAAEAAEEAQKK GGSSGGSGG EQLQLHALMAIKFKQAEEEAEEAQEL
1: NE = no expression, E = expression successful, C = fusion protein successfully cleaved, P = protein fully purified and stable
HS-9-W
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E,C,P
E,C,P
NE
E,C,P
E,C,P
E,C,P
E,C,P
E,C,P

Finally, another separate library of sequences was generated to explore the additional
effect of lowering the overall hydrophobic content of our protein sequences. In this case, the
original discrete probability distribution for amino acid occupancy shown in Table 2 was
modified to exclude the hydrophobic residues leucine and isoleucine from occupying interfacial
(neutral) positions. The resulting distribution is shown in Table 7 below. The ten sequences
(HSH-1 to HSH-10) shown in Table 8 were then generated using this new probability
distribution as well as the modified net charge cutoff rule and expanded consensus sequence, as
described above.

Table 6. Modified amino acid probability distributions for each position category in the HSH protein library. Each
entry represents the probability (normalized to 100%) that the corresponding residue will appear in the given
position category.

Residue
A
E
F
I
K
L
M
Q
R
V

Core Probability
15.8
0.0
13.8
17.4
0.0
19.3
20.1
0.0
0.0
13.4

Surface Probability
20.6
21.3
0.0
0.0
19.5
0.0
0.0
19.7
18.7
0.0
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Interface Probability
28.4
21.5
0.0
0.0
23.2
0.0
0.0
26.9
0.0
0.0

Table 7. The HSH protein sequences and the steps in the purification process that were possible for each sequence. Helical regions are underlined and fixed
amino acid identities are highlighted in bold for each sequence.
Name
Sequence
Purification
Step1
RKLKKHAEEAIAMKRKAKKAAREAER GGSNSGSGG AQLARHARQAIAAVKAAERAAARAQR GGSSTGSGG
AALEKHAKMAIKMQAAARKAERAKKA GGSSGGSGG KALKMHAQLAIQIAKAAQQAAQAAKK
HSH-1
E,C,P
HSH-2
HSH-3
HSH-4
HSH-5
HSH-6
HSH-7
HSH-8
HSH-9
HSH-10
HSH-1-W

KALAQHARAAIKFQQEAKKAARQAER GGSNSGSGG KQLRQHAQAAIAMMAAAQRAAARAKR GGSSTGSGG
KALEEHARLAIAAKKAAKKAQQAAQK GGSSGGSGG KQLEIHAQMAIAARKAQRQAKQAQKA
AKLRRHAEEAIEVQKKAAQAARAAKK GGSNSGSGG RALREHAEAAIRVMRQAKKQAQQAKR GGSSTGSGG
AKLEAHARIAIQARQAKKEAQQAKRR GGSSGGSGG EKLRVHAQFAIAVKKAAQQAKRAKQA
AKLRKHAEAAIRAKQQAAAAARAAQQ GGSNSGSGG AQLKKHARAAIEVLRAAAKAAQKAKR GGSSTGSGG
RELAKHAKMAIKLEAAARKAARAAKQ GGSSGGSGG EKLKLHAKMAIQVRRAAQAAQKAQEK
RQLKKHAEAAIQLARKAEQAAQKAQK GGSNSGSGG AQLKEHAAAAIKMFAQAKEKAQRAKK GGSSTGSGG
RALEEHAKFAIKVRKAEKKAEQAKKQ GGSSGGSGG KKLEMHAAMAIEMAAAQRQARKAKRQ
EELQAHAKEAIAAKEQAAEAAEEAQQ GGSNSGSGG QELEEHAAKAIEVAEQAQEEAQEAEQ GGSSTGSGG
QALAQHAQMAIAAEQAEEEAEKAEQE GGSSGGSGG EALELHAKIAIAAERAAEQAEEAAEQ
KELQEHAEEAIQAEKAAEEAAEQAEA GGSNSGSGG EALAEHAKAAIQLMEEAEEAAEQAQR GGSSTGSGG
RALEEHAELAIQLEAAAEAAEEAQAA GGSSGGSGG QELAMHAEAAIKAQEAAAQAEEAQEQ
EQLRQHAEQAIEMAEQAKEAAEKAEE GGSNSGSGG RELEEHAAQAIQVMAQAEEQAERAAE GGSSTGSGG
QALEQHAQMAIELERAAEAAEAAEAA GGSSGGSGG AALEFHAEFAIAMAEAKREAEQAEAE
AALQQHAEAAIALQAEAAEAAEQAAE GGSNSGSGG AELEQHAEQAIKAIEEAEAQAARAEA GGSSTGSGG
EALQAHAQMAIEAREAAEAAEQAEAE GGSSGGSGG EELELHAQLAIKMREAEEQAQQAKEE
EALAEHAAQAIAIEEQAQKAAEQAEE GGSNSGSGG EELAEHAEQAIQAFREAAEAAQAAEQ GGSSTGSGG
QALEEHAEAAIEMRKAAEEAAQAQEA GGSSGGSGG QALEFHAALAIAVQQAQAQAEEAEEQ
RKLKKHAEEAIAMKRKAKKAAWEAER GGSNSGSGG AQLARHARQAIAAVKAAERAAARAQR GGSSTGSGG
AALEKHAKMAIKMQAAARKAERAKKA GGSSGGSGG KALKMHAQLAIQIAKAAQQAAQAAKK

1: NE = no expression, E = expression successful, C = fusion protein successfully cleaved, P = protein fully purified and stable
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E,C
E,C
E,C
E,C
E,C,P
E,C,P
NE
E,C,P
E,C,P
E,C,P

4.3 Materials and Methods
4.3.1 Protein Preparation. Genes encoding all twenty sequences were purchased from
Biomatik, Inc. (Cambridge, ON) with an N-terminal TEV cut site inserted between the BamHI
and XhoI restriction sites of pET32a (+) (Novagen), which expresses proteins as His6-tagged
thioredoxin fusions.29 Site-directed mutants were generated using the Quickchange XL Site
directed mutagenesis kit (Agilent Technologies, Santa Clara, CA).
Protein purification via Ni-NTA column was performed according to the protocol
described in Section 3.2.1 above, with the following two modifications: 1) His6-tagged fusion
proteins were purified under native conditions using traditional wash (50mM NaH2PO4, 300mM
NaCl, 20mM Imidazole, pH 8.0) and elution (50mM NaH2PO4, 300mM NaCl, 250mM
Imidazole, pH 8.0) buffers; and 2) fusion proteins were cleaved under native conditions in 50mM
Tris-HCl, 0.5mM EDTA, 1mM DTT, pH 8.0.
4.3.2 Nuclear Magnetic Resonance Spectroscopy. Uniformly 15N labeled samples were
prepared in 100mM NaH2PO4, 50mM NaCl, pH 6.0 with 10% D2O added before data
collection. Two-dimensional 1H-15N sensitivity-enhanced constant-time heteronuclear singlequantum coherence (15N-HSQC) spectra were collected as described previously.29

4.4 Characterization of Next Generation Sequences
4.4.1 Solubility and Heme Binding. The expression and purification results for the HS
and HSH libraries are shown in Table 6 and Table 8, respectively. Of the ten sequences in the HS
library, four were successfully expressed and purified. With the exception of HSH-8, which
could not be overexpressed, all of the negatively charged sequences in the library remained
soluble throughout the entire purification process. Of the soluble HS sequences (HS-6, HS-7,
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HS-9, and HS-10), three sequences (HS-7, HS-9, and HS-10) were found to bind heme in a
preliminary assay (Figure 12). In order to correctly determine the solution protein concentration
and thus quantify the stoichiometry of binding, each sequence was mutated to include a
tryptophan residue at the end of the first helix (Table 6). In all three cases, the sequences were
found to bind one molecule of heme per four-helix bundle.

Figure 12. Heme binding in the HS protein library. Selected spectra are characteristic of bound heme in the
presence of (A) HS-7, (B) HS-9 and (C) HS-10.

Five out of the ten sequences in the HSH library could be successfully expressed and
purified. As with the HS library, the majority of the soluble sequences were highly negatively
charged with the notable exception of the positively charged HSH-1 sequence. Of these soluble
sequences (HSH-1, HSH-6, HSH-7, HSH-9, and HSH-10), only the positive sequence HSH-1
was found to bind heme. As with the HS proteins, this sequence was found to bind one molecule
of heme per four-helix bundle.
4.4.2 Structural Characterization. HS-7, HS-9, and HS-10 were soluble at high
concentrations at pH 6.0 and thus permitted the collection of 15N-HSQC spectra as shown in
Figure 13 below. As the solubility of HSH-1 was highly limited at pH 6.0, no acceptable data
could be produced on the backbone structural specificity of this sequence. HS-9 and HS-10 in
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particular exhibit a high degree of chemical shift dispersion in the apo state, and appear to
undergo further structural changes upon heme binding.
The negatively charged HSH sequences (HSH-6, HSH-7, HSH-9, and HSH-10) were
assayed for helical content via CD spectroscopy. Their spectra (Figure 14) are characteristic of a
random coil backbone conformation, even at increased salt concentrations (not shown). These
spectra may serve to explain the lack of heme binding observed in these sequences, as they lack
the requisite secondary structure for a molten globular apo state.
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Figure 13. NMR structural characterization of the soluble, heme-binding HS series proteins. (A) 15N-HSQC
backbone spectra of uniformly 15N-labeled apo HS-7, and (B) the corresponding spectra of holo HS-7. (C) 15NHSQC backbone spectra of apo HS-9 and (D) the corresponding spectra of holo HS-9. (E) 15N-HSQC backbone
spectra of apo HS-10 and (F) the corresponding spectra of holo HS-10. Each of these sequences, and especially HS10, displays an overall increase in chemical shift dispersion upon interaction with heme.

46

Figure 14. Structural characterization of the HSH proteins. (A) HSH-6, (B) HSH-7, (C) HSH-9, and (D) HSH-10 all
exhibit the characteristic CD spectra of a random coil. Due to their high net charge and low hydrophobicity, these
proteins cannot adopt the molten globular state required for heme binding.

4.5 Implications for Future Design Procedures
The goal in modulating the hydrophobicity and net charge parameters in the
aformentioned design procedure was to increase the solubility of the resulting sequences, and
thereby enhance the success rate of the procedure as a whole. While that goal was not met in the
case of all sequences in either the HS or HSH sequence libraries, the above results indicate that
such an increase can nevertheless be achieved in future design efforts through a careful
consideration of those parameters.
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With the sole exception of HSH-1, no positively charged sequence in either library could
be successfully purified using the methods detailed in Section 4.3.1. Conversely, except for HS-8
and HSH-8, neither of which could be overexpressed, every negatively charged sequence in both
libraries could be purified with the same methods. These results agree with previous studies
showing a strong positive correlation between solubility and negative surface charge count in
natural proteins.78,79 This is most likely due to the differential hydration of the charge-carrying
groups of positive and negatively charged amino acids,80 a fact that might account for the
observed preference for negatively charged proteins throughout the proteome.81 Therefore, future
versions of the protein design scheme described in Chapter 2 should see dramatically improved
success rates if a negative net charge is imposed on all sequences. Further study is needed to
determine the optimal range of net charge for functional sequences.
Figure 13 in Section 4.4.2 shows that the supercharged proteins HS7, HS9, and HS10 are
molten globular in the apo state, and become more structured upon interaction with heme. This
behavior indicates that the strong heme binding interaction sufficiently accounts for any
nonspecific hydrophobic packing in the protein core.29 Most of the soluble HSH sequences were
unable to bind heme and exhibited a preference for a random coil conformation (Figure 14).
These two observations suggest that these proteins may be too highly charged and insufficiently
hydrophobic to adopt the molten globular conformation requisite for heme binding.82 These
results imply that supercharging alone may be sufficient to enhance the solubility of designed
protein sequences, and that restricting the placement of hydrophobic residues might in fact be
detrimental to proper folding.
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Chapter 5: Engineering a Functional Di-Mangnese Enzyme

5.1 Background
5.1.1 The Oxygen Evolving Complex. In order to fulfill its potential as a robust,
renewable, and clean energy source, solar irradiation must first be efficiently harvested and
converted to a useable form. Natural photosynthetic organisms ‘solved’ the problem of
converting solar energy into chemical energy about 2.5 billion years ago by using water as an
electron source.83 Water is highly abundant and inexpensive, and as such is an ideal raw material
for the formation of chemical fuels. Accordingly, one promising approach to solar fuel
generation is to recreate and repurpose the essential water-splitting mechanism of natural
photosynthesis using the tools of synthetic biology.6,84
Natural photosynthetic water oxidation occurs in the oxygen-evolving complex (OEC), a
metal center located in the protein complex Photosystem II. The OEC consists of four
manganese atoms and one calcium atom arranged in a distorted cubane-like structure, with five
oxygens serving as oxo bridges between the metals (Figure 15A).85 To be able to perform the
four-electron oxidation of water, the OEC accumulates the necessary oxidizing equivalents via
four successive oxidations by the chlorophyll center P680.86,87 Crucially, the midpoint potential of
the S3/S4 state couple of the OEC is above that of H2O/O2 at around 1.2V. The water splitting
reaction then provides the electrons necessary to reset the OEC back to its most reduced state
(S0), whereupon the cycle can begin again (Figure 15B).87
Decades of research into the structure and chemical mechanism of the OEC have
uncovered various design principles for a photosynthetic water splitting catalyst.84 Chemists have
subsequently implemented and greatly extended these principles by building simplified,

49

functional OEC model systems.88-90 Of particular interest is a family of oxo-bridged dinuclear
manganese complexes, the first of which was synthesized by Brudvig in 1999.91 The success of
these complexes indicates that a stable dimanganese metal center with reduction potential above
that of the H2O/O2 couple and an open site for substrate water may be sufficient requirements for
a model water oxidation catalyst.7

Figure 15. Structure and function of the Oxygen Evolving Complex (OEC) of Photosystem II. (A) The geometry of
the metal center of the OEC, which consists of four oxo-bridged manganese atoms and a single calcium atom in a
distorted cubane-like arrangement. Figure adapted from the structure published by Umena et al.85 (B) The catalytic
cycle of the OEC consists of four subsequent oxidations of the metal center via electron transfer to the P 680
chlorophyll molecule (S0 to S4), followed by a four-electron reduction of the metal center via water oxidation (S4 to
S0).87

5.1.2 Manganese Catalase. Manganese catalase is a binuclear manganese enzyme found
in a wide range of organisms that catalyzes the disproportionation of hydrogen peroxide into
water and dioxygen (Eq. 5):92
(5)

2H2 O2 ⟶ O2 + 2H2 O

Unlike the well-known heme-containing catalases, manganese catalase performs the above
chemistry via two one-electron half-reactions wherein its metal center cycles between reduced
Mn(II,II) and oxidized Mn(III,III) states (Eqs. 6 and 7):92
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(6)

H2 O2 + {Mn2 (III,III)} ⟶ O2 + {Mn2 (II,II) + 2H + }

(7)

H2 O2 + {Mn2 (II,II) + 2H + } ⟶ 2H2 O + {Mn2 (III,III)}
Manganese catalase isolated from L. plantarum contains a solvent-accessible oxo-bridged

dimanganese complex at the center of a four-helix bundle domain (Figure 16).93 This type of
binuclear metal center is relatively common in nature and found in enzymes as diverse as
methane monooxygenase and ribonucleotide reductase.94 In manganese catalase, it is stable
through multiple oxidation states, has openings for substrate H2O2, and can catalyze O-O bond
formation.92 Parallels with the OEC have not gone unnoticed, as it has been investigated as a
structural model for the S2 state of that complex.95,96

Figure 16. The structure of manganese catalase from L. plantarum with a single subunit highlighted in blue. This
protein is homohexameric with subunits arranged into a shell surrounding a solvent-filled central cavity.92 Each
subunit contains a four helix bundle domain housing a dimanganese active site. Figure adapted from crystal structure
published by Whittaker et al.93
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Manganese catalase catalyzes a well-known reaction using a cofactor motif that has been
thoroughly studied and is common across many enzymes. These characteristics make it an
attractive target for de novo protein design efforts. A functional synthetic manganese catalase
enzyme is an achievable goal, and its design will inform that of future polypeptide models of the
OEC.
5.1.3 The DF Series. The DF series of di-metal binding proteins, developed by DeGrado
and coworkers early in the last decade, was a foundational achievement in protein design: the
implantation of a common biological cofactor motif, the carboxylate-bridged dinuclear metal
center, into a simple, robust four alpha helical bundle (Figure 17).97,98,99 This is the same
catalytic cofactor found manganese catalase.94 As proof that this radical structural simplification
is nevertheless enzymatically active, DeGrado has shown that the di-iron form of DF2 is a
functional phenol oxidase enzyme.100 The binuclear active site of DF2 has been shown to
accommodate many different metal ions including manganese,101 indicating that the DF
backbone shows promise as a platform upon which to engineer other redox-active enzymes.

Figure 17. Crystal structure of the di-manganese form of the homodimeric DF backbone.101 Metal-ligating residues
are shown.
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Figure 18. Comparison of the di-mangnaese active sites of (A) DF1101 and (B) Manganese Catalase.93 Both consist
of oxo-bridged di-nuclear manganese clusters at the center of a four-helix bundle domain, ligated by three glutamate
and two histidine residues.

The DF backbone is structurally homologous to wild-type manganese catalase. Both
proteins adopt an overall four-helix bundle motif and employ Glu and His side chains to ligate
the metals in approximately the same carboxylate-bridged configuration (Figure 18). The dimanganese form of DF1, however, fails to exhibit catalase activity likely due to an overall lack
of flexibility, a lack of solvent accessibility at the metal site, and/or a failure to stabilize the
oxidized form of manganese necessary for catalysis.102

5.2 Re-Engineering an Artificial Di-Manganese Protein
5.2.1 Topology Modification. To fashion a manganese catalase based on the
homodimeric DF platform, the single chain monomeric protein (termed CDM2) was created by
connecting two additional helices to the original DF2 monomer via two glycine-rich ‘strap’
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regions as shown in Figure 18. The single-chain has at least two distinct advantages over a
homodimeric four-helix bundle topology. First, a modular single-chain structure can support
non-symmetric mutations to the protein sequence. Such mutations are necessary for attachment
to electrode surfaces or fine-tuned control of the second shell residues of the active site. Second,
the use of flexible ‘strap’ regions rather than helical turns and the reversed orientation of helices
1 and 4 encourage a greater overall flexibility in the protein backbone. By swapping these
helices, the number of highly specific core packing interactions has been reduced in the bundle
without deleteriously affecting the active site or the binary patterned sequence of each helix.
Such a significant overhaul of the topology is only possible because the cofactor binding
sequence is both symmetric and at the center of each of the four helices.
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Figure 19. Sequence and topology representation of DF2, CDM2, and CDM13. Residues participating in metal
ligation are highlighted in yellow. (A) The amino acid sequence of the DF2 homodimer with helices and loop
sections indicated. (B) The amino acid sequence of CDM2, consisting of a monomer of DF2 connected via glycinerich ‘strap’ regions at each terminus to two additional helices. (C) CDM13 with mutations to enhance the solvent
accessibility to the metal center (shown in red). (D) A schematic of the topology of DF2. The helix labels
correspond to those in part A. (E) The topology of CDM2 and CDM13, which is distinct from that shown in part D.
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5.2.2 Active-Site Modification. A commonality of many computationally designed
artificial proteins which bind cofactors or metals is an overly stabilized apo state with low
solvent accessibility to the binding pocket, and the progression from multimeric to monomeric
designs appears to exacerbate this problem. An open state competent for cofactor binding thus
requires a significant degree of unfolding before binding can occur, and in some cases,
destabilizing mutations must be introduced in order to expand the apoprotein conformational
ensemble.103 Recently, Lombardi et al showed that the mutation of two key residues of di-ferric
DF2 resulted in increased solvent accessibility via the partial destabilization of individual
helices.104 Adapting this idea to CDM2, four mutations (L37G, L41G, L91G, and L95G) were
made to the sequence (Figure 19 and Figure 20). This new sequence was termed CDM13.

5.3 Materials and Methods
5.3.1 Protein Preparation. Genes encoding CDM2 and CDM13 were purchased from
Biomatik, Inc. (Cambridge, ON) with an N-terminal TEV cut site inserted between the BamHI
and XhoI restriction sites of pET32a (+) (Novagen), which expresses proteins as His6-tagged
thioredoxin fusions29. Protein purification was performed using the non-denaturing protocol as
described in Section 4.3.1. Purified proteins were dialyzed into 20mM Ammonium Bicarbonate,
2mM Glucose, pH 7.5 and lyophilized.
5.3.2 Metal Complex Formation. Mn(II) binding by CDM-13 was monitored by circular
dichroism (CD) spectroscopy. CD spectra were recorded on a JASCO J-810 spectropolarimeter
in a 0.1cm quartz cuvette, using a bandwidth of 1nm and a scan speed of 50nm/min. Aliquots of
a freshly prepared aqueous solution of MnCl2 were added to peptide solution (10 – 20 uM
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protein, 10mM HEPES, pH 7.0), and samples were allowed to equilibrate for at least 30 minutes
prior to data collection.
5.3.3 Nuclear Magnetic Resonance Spectroscopy. NMR spectroscopy was performed
as described in Section 4.3.2. Uniformly 15N-labeled lyophilized protein stock was suspended in
50mM NaH2PO4, pH 6.5 with 10% D2O added before data collection. Experiments were
performed at a four-helix bundle concentration of 100 µM. A freshly prepared aqueous stock
solution of ZnCl was added to apo-CDM13 and samples were allowed to equilibrate for at least
30 minutes before data collection.
5.3.4 Electron Paramagnetic Resonance Spectroscopy. EPR Spectroscopy was
performed in the laboratory of Prof. Gary Brudvig at Yale University, with the generous
assistance of Dr. David Vinyard. EPR spectra were obtained on a Bruker ELEXYS E500
spectrometer equipped with a SHQ resonator and an Oxford ESR-900 helium flow cryostat.
Spectra were measured at 6.0-6.5 K using the following instrumental parameters: microwave
frequency, 9.36 GHz; modulation frequency, 100 kHz; modulation amplitude, 19.5 G;
microwave power, 20 mW.
5.3.5 Catalytic Activity Measurement. The activity of CDM-13 was assayed by UV-Vis
spectroscopy. Optical Spectra were collected with a Hewlett-Packard (New York, NY) 8452A
Diode array spectrophotometer running the Olis (Bogart, CA) SpectralWorks software. A freshly
prepared solution of H2O2 (1 – 20mM) was added to peptide solution (10uM in 100mM
NaH2PO4, pH 7), and the mixture was immediately and thoroughly mixed. The
disproportionation of H2O2 was monitored by the concomitant loss of absorbance at 240nm. The
reaction was monitored over a 15-minute time course to determine the rate of H2O2
disproportionation.
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5.3.6 Stopped-Flow Analysis. The ‘burst phase’ kinetics of hydrogen peroxide
disproportionation were analyzed in rapid stopped-flow mixing experiments by monitoring H2O2
absorbance at 240nm using a Biologic (Lyon, France) SFM 300 stopped-flow mixer with a
Biologic MOS 200 detector configured for single wavelength detection. Measurements were
standardized with H2O2 solutions ranging from 0 – 25mM to yield a conversion factor of 0.021
AU per millimolar H2O2. 50mM phosphate buffer pH 7.0 was mixed with H2O2 solution in the
first mix, and both were subsequently combined with holo-CDM13 in the second mix.
5.3.7 Aperometry. Amperometry was perfomed on CDM13 in the laboratory of Prof.
Shelly Minteer at the Univerity of Utah with the kind help of Dr. Fabien Giroud. A three
electrodes set-up was used for all the electrochemical experiments. Saturated calomel electrode
and platinum mesh were used as the reference and the counter electrodes, respectively.
Electrochemical tests were performed on basal plane HOPG electrodes as working electrodes.
The electrodes were polished with 1 µm and 0.05 µm alumina powders thoroughly rinse with DI
water, EtOH and sonicated for 5 min in EtOH. The electrodes were dried over a nitrogen flow.
Then, 25 µL of a 2 mg/mL solution of CDM13-Mn were drop casted onto the graphite electrode
and the protein film was allowed to dry in a desiccator under vacuum for 1 hour. Control
experiments consisted of omitting the enzyme layer onto the graphite surface in presence of
substrate. Blank experiments were performed without enzyme and without substrate. Cyclic
voltammetry experiments were performed at 100 mV/s in 50 mM sodium phosphate, 100 mM
sodium nitrate at pH = 7.0, in absence or presence of 5 mM H2O2 and only the second scan is
shown. Chronoamperometry experiments were carried out at 650 mV vs. SCE. All experiments
were realized inside a glove box under N2. During chronoamperometry experiments, dissolved
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O2 was monitored using an oxygen probe. The same probe was used previously to ascertain the
solution was free of O2.

5.4 Characterization of a Functional Manganese Catalase Mimic
5.4.1 Metal-Binding Stoichiometry and Active-Site Characterization. As discussed in
Section 5.2.1, the change in topology from DF2 to CDM2 was performed in part to destabilize
the apo state of the protein and facilitate metal binding without the use of denaturants. However,
even with the helix reversal, CDM2 does not detectably bind either Mn(II) or Co(II) after 16
hour incubation times as observed optically, by isothermal titration calorimetry, or using circular
dichroism (not shown).
Figure 20. Increasing solvent accessibility at the dimetal active site. (A) Four leucine residues (red) block access to
the active site of CDM2. (B) Those four positions (red) were mutated to glycine in CDM13.

To create the CDM13 sequence, four leucine residues blocking solvent access to the
binding site in CDM2 were replaced by glycine (Fig 20B). As a result, CDM13 binds two
equivalents of Mn2+ on a minutes time scale concomitant with a change in its alpha helical
content (Figure 22, Left). As has been observed with other designed helical bundle proteins,105
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apo-CDM13 appears to be partially molten globular as observed by NMR and the addition of
two equivalents of Zn induces an ordering of the protein to a nativelike holoprotein state (Figure
21).
Figure 21. Changes to the CDM13 backbone upon interaction with metal atoms. 600MHz 15N-HSQC Spectra of
150uM CDM13 in 50 mM NaH2PO4, pH 6.5 at 25C. (A) Apo CDM13 exhibits poor chemical shift dispersion and is
likely molten globular. (B) Two atoms of Zn per bundle results in greater chemical shift dispersion.
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Figure 22. (Left) Binding of Mn2+ to apo-CDM13. Circular dichroism (CD) spectra of 10uM CDM13 in 10uM ??,
pH 7 at 25C. Representative CD spectra of CDM13. Stepwise addition of Mn2+ as MnCl2 results in a signal decrease
at 220nm. Inset is a plot of the normalized CD signal at 220nm vs atoms of Mn 2+ per bundle, exhibiting a break
point at 2 Mn/Bundle. (Right) Full EPR spectra of holo-CDM13 at 6.0-6.5K after brief incubation with EDTA to
minimize signal from unbound Mn2+. Inset is the detailed spectrum of a broad feature at g=1.98, exhibiting
hyperfine peaks spaced 45 +/- 1 G apart. These hyperfine features are characteristic of an antiferromagnetically
coupled Mn2+- Mn2+ dimer with ions spaced between 3.1-3.7A apart.

EPR analysis of the bound Mn(II) enables the confirmation of di-nuclear metal center
assembly. In order to avoid overlapping signals from surface-bound Mn2+, 10mM EDTA was
added to a mixture of 600μM CDM13 and 1mM MnCl2 in a quartz EPR tube, incubated for 20 s,
a time chosen to allow chelation of free Mn2+ but not significant extraction of Mn2+ from the
protein, and then quench cooled in liquid nitrogen.106 The EPR spectrum of holo-CDM13
following this brief EDTA incubation is shown in Figure 22. The spectrum consists of a broad
feature centered at g = 1.98 (peak-to-peak width ~560 G) overlaid with ~17 hyperfine features
spaced 45 ± 1 G apart. This hyperfine-coupling constant is diagnostic for 55Mn in an
antiferromagnetically coupled Mn2+-Mn2+ dimer.107,108 In accordance with previous studies at
low temperature (≤15 K),108-110 the observed spectrum was assigned to the first excited state
(S=1) of a weakly coupled Mn2+-Mn2+ dimer. While the Mn-Mn distance cannot be accurately
determined without knowledge of the zero-field splitting interaction, a survey of model
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complexes and Mn-containing enzymes containing similar weakly coupled Mn2+-Mn2+ dimers
found a range of 3.1-3.7Å.110

5.4.2 Catalytic Activity.
Figure 23. Catalytic activity of CDM13. (Left) Michealis-Menten plot of steady-state H2O2 disproportionation
catalyzed by holo CDM13. Inset is a representative trace of solution O2 concentration in the presence (orange) and
absence (blue) of CDM13. (Right) Investigation of the ‘burst phase’ of CDM13-catalyzed H2O2 disproportionation.
A typical time-course measurement of peroxide absorbance at 240nm during the reaction features a high-rate ‘burst
phase’ followed by a steady-state disproportionation rate. Inset is a plot of the rate of this phase as a function of holo
CDM13 concentration as determined by stopped flow analysis.

Assembled di-manganese CDM13 catalyzes the disproportionation of hydrogen peroxide
under steady-state conditions with kcat and Km values of .084 ± .002 sec-1 and 5.1 ± 0.5 mM,
respectively, as monitored both by the disappearance of the peroxide absorbance at 240 nm
(Figure 23, Left) and by the rate of production of oxygen (Figure 23, Left Inset). When the
protein is mixed with hydrogen peroxide in a stopped-flow spectrophotometer, however, a
significant catalytic burst is observed (Figure 23, Right), which is second order both in protein
and hydrogen peroxide (Figure 23, Right Inset). The mechanism of this complex catalytic
behavior is unclear. Natural manganese catalases exhibit similar behavior, forming EPR-
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observable trapped Mn3+/Mn4+ states that are inactive until re-reduced by an exogenous reducing
agent.111 However, CDM13 frozen while undergoing steady state turnover is EPR silent, and
during steady-state turnover with protein concentrations as high as 600 µM, no manganese
intermediates can be detected optically. HPLC-MS analysis demonstrates that the protein does
not change mass after catalyzing >106 turnovers, and protein re-isolated after catalysis using a
desalting column exhibits the same burst behavior, within error, as was observed the first time.

Figure 24. (Left) Representative chronoamperometric measurements and of bare basal plane electrodes (dashed
line) and holo-CDM13 electrodes (solid line) upon successive addition of different concentration of H 2O2. (Right)
The calibration curve generated from the measurements on the left. Dashed lines represent fitting using the
Michaelis-Menten equation.

Catalytic wave voltammetry performed on the di-manganese complex using a basal plane
highly-oriented pyrolytic graphite (HOPG) electrode exhibits a significant rate of catalysis in the
oxidative half reaction (Figure 24), but no observable current in the water-forming reductive half
reaction. Amperometric analyses carried out with the working electrode set at +890 mV over a
range of hydrogen peroxide concentrations (Figure 24B) demonstrate a maximal current density,
Jmax, of 1184 ± 9 µA/cm2 with a half-saturating substrate concentration of 27.7 ± 0.1 mM. This
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current allows for the calculation of the lower limit of the kred for the reductive half reaction –
assuming perfect monolayer formation with the helical bundle laying on its side, 9.25x1012
CDM13 molecules will assemble per cm2. Dividing the observed current by this value gives a
lower limit for kred of 400.0±0.2 s-1. Given the overall kcat of 0.08 s-1, Eq. 8112 can be used to
demonstrate that the oxidative half reaction is completely rate-limiting, with an upper limit of
0.08 s-1 for the rate.
(8)

𝑘

𝑘

𝑘𝑐𝑎𝑡 = 𝑘 𝑜𝑥+𝑘𝑟𝑒𝑑
𝑜𝑥

𝑟𝑒𝑑

Experiments were also performed in an electrochemical cell containing an oxygen probe in order
to quantify the production of O2 from the enzymatic reaction. The same trends observed in
chronoamperometry can be drawn from the oxygen production assay in Figure 25.
Figure 25. Calibration curves of oxygen production generated from successive injections of H2O2 during
chronoamperometric measurements for bare electrode (empty square) and holo CDM13 (black square). The O2
concentration was taken 10 seconds prior a new injection. The empty circles represent independent experiment
where only [O2] was recorded with successive injection of the H2O2 solution.
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5.4.3 Electrochemical Potentials of Metals. To determine the midpoint potential of
CMD13, cyclic voltammetry experiments were performed in the potential window where the
enzyme communicates with the electrode (Figure 26). In absence of oxygen, bare electrodes
clearly do not show any signal from 0 to 1 V vs. SCE. Modified-basal plane graphite electrodes
modified with the enzyme showed a redox peak, Epc (the cathodic peak potential) and Epa (the
anodic peak potential) were found to be +670 and +940 mV vs. NHE, respectively. The scan
rate-dependence of the peak areas predicts that 2.0 ± 0.1 electrons are transferred in each
transition.
Figure 26. Background-subtracted cyclic voltammogram of a CDM13-modified basal plane graphite electrode in
50mM NaH2PO4, 100 mM nitrate, pH 7.0 at 100 mV/s in the absence of H 2O2. Inset is the raw cyclic
voltammogram of CDM13 overlaid with the signal from the unmodified electrode.
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5.5 Implications for Future Artificial Manganese Enzymes
CDM13 exhibits a catalytic efficiency about 106-fold lower than that of wild-type
manganese catalase. Another carboxylate-bridged binuclear manganese enzyme, arginase, has
been shown to exhibit catalase activity even lower than that of CDM13.113 The great difference
in catalytic activity between arginase and manganese catalase, despite their high degree of
structural similarity, has been attributed to a difference in the Mn(II)-Mn(III) midpoint potential
between manganese catalase and these structural mimics.114
In studies with Manganese Superoxide Dismutase (MnSOD), Vance and Miller
demonstrated that the optimal Em for MnSOD is midway between the potentials of the two halfreactions it catalyzes, and any changes to this Em result in a decrease in overall catalytic
activity.106 The two electron midpoint potential of CDM13, +805 mV is only slightly below that
of the O2/H2O2 couple, +850 mV, but significantly higher than that of the H2O2/H2O couple. This
provides an explanation for the low catalase activity displayed by CDM13 despite its ability to
self-assemble a manganese catalase-like active site – the driving force for the reductive half
reaction is too small. This further explains the large difference observed in the rates of the
CDM13-catalyzed half reactions: the oxidative half-reaction has more than 0.8 V of driving force
while the reductive half-reaction has less than 100 mV.
Finally, while the Mn2+/3+ couple reduction potential of CDM13 is too high to efficiently
catalyze the dismutation of hydrogen peroxide, the Mn3+/4+ couple, assuming Mn4+ can be
stabilized in CDM13, has a potential too high to be measured using an HOPG electrode. As
mentioned earlier, such a high potential is necessary for any successful water oxidation catalyst
because of the nature of the H2O/O2 midpoint potential.18 Work is underway both to determine
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the Mn3+/4+ oxidation potentials of CDM13 and to test the Mn4+ complex for its ability to oxidize
water.
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